RSC Advances
·
2022
·Vol. 12
·期 54
·35477-35483
·
IF 4.036
Lihong Li,Qi Zhang,Jiaojiao Li,Yafei Tian,Jinyao Li,Wen Liu,Haipeng Diao
Phototheranostic probes have been proven to be a promising option for cancer diagnosis and treatment. However, near-infrared phototheranostic probes with specific tumor microenvironment responsiveness are still in demand. In this paper, a carboxylesterase (CES)-responsive near-infrared phototheranostic probe was developed by incorporating 6-acetamidohexanoic acid into a hemicyanine dye through an ester bond. The probe exhibits highly sensitive and selective fluorescence enhancement towards CES because CES-catalyzed cleavage of the ester bond leads to the release of the fluorophore. By virtue of its near-infrared analytical wavelengths and high sensitivity, the probe has been employed for endogenous CES activatable fluorescence imaging of tumor cells. Moreover, under 660 nm laser irradiation, the probe can generate toxic reactive oxygen species and efficiently kill tumor cells, with low cytotoxicity in dark. As far as we know, the probe was the first CES-responsive phototheranostic probe with both near-infrared analytical wavelengths and photosensitive capacity, which may be useful in the real-time and in situ imaging of CES as well as imaging-guided photodynamic therapy of tumors. Therefore, the proposed probe may have wide application prospect in cancer theranostics.
研究领域:
癌症诊断与治疗
·
生物医学工程
·
分子成像
·
光动力治疗
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Advanced Science
·
2022
·Vol. 10
·期 4
·2205320
·
IF 17.521
Ruoping Wang,Junpeng Shi,Qian Zhang,Qiang Peng,Xia Sun,Liang Song,Yun Zhang
Rheumatoid arthritis (RA) is a common, chronic, and highly disabling autoimmune disease characterized by difficult treatment, long disease duration, and easy recurrence. The development and application of high-sensitivity theranostic probes for RA that will facilitate precise monitoring of disease progression and enable effective treatment are currently hotspots in the field of RA theranostics. In this study, mZMI@HA, a dual-triggered theranostics nanoprobe, is constructed based on near-infrared persistent luminescence nanoparticles (NIR-PLNPs) for precise RA treatment and therapeutic evaluation. This is the first reported use of high-sensitivity autofluorescence-free imaging based on NIR-PLNPs for precise RA treatment and therapeutic evaluation. Compared with the NIR fluorescence imaging probe-indocyanine green, the signal-to-background ratio of persistent luminescence (PersL) imaging is improved nearly 14-fold. Using PersL imaging to guide photothermal therapy and controllable drug release through NIR/pH-responsiveness, the progress of collagen-induced RA is relieved. Additionally, the therapeutic evaluation of RA by PersL imaging is consistent with clinical micro-computed tomography and histological analyses. This study demonstrates the potential of NIR-PLNPs for high-sensitivity imaging-guided RA treatment, providing a new strategy for RA precise theranostics.
研究领域:
生物医学工程
·
诊疗学
·
纳米技术
·
成像科学
·
风湿病学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
CHEMICAL ENGINEERING JOURNAL
·
2021
·
IF 13.273
Hui Zhang,LianXiao Zhang,Hua Zhong,Shuyan Niu,Caifeng Ding,Shaoping Lv
A novel iridium oxide nanoparticles-based probe was developed for in vivo fluorescence imaging of microRNA and synergistic chem/photothermal treatments of tumor. The theranostic nanoprobe was constructed by functionizing iridium oxide nanoparticles with split DNAzyme precursor and chemotherapeutic agent doxorubicin. The split DNAzyme precursor was used for specifically recognizing the target microRNA in cancer cells and then releasing the preloaded fluorescence for detection through DNAzyme cleavage reaction. Because the fluorescence was enhanced by cycle amplification process, the nanoprobe exhibited high sensitivity in the cell-free test. Both in vitro and in vivo fluorescence imaging studies proved the specificity and feasibility of the nanoprobe in tumor imaging. In order to enhance the effectiveness of cancer cell therapy, synergistic chem/photothermal treatments were designed on the nanoprobe. Based on the photothermally controlled drug release and chemotherapeutic treatment of doxorubicin, and the photothermal effect of iridium oxide nanoparticles, the nanoprobe exhibited excellent synergy effect on cancer cell treatment under near-infrared irradiation. In particular, in vivo therapeutic studies proved a great inhibition of the tumor growth. Therefore, this work provided a promising theranostic nanoprobe for both tumor imaging and synergistic treatment of cancer cells.
研究领域:
纳米技术
·
癌症治疗
·
分子生物学
·
生物医学工程
·
诊疗学
✓ 已验证
产品关联
DOI
高影响因子
CHEMICAL ENGINEERING JOURNAL
·
2024
·
IF 13.3
Mengjie Sun,Zhouyu Zhang,Chang Yin,Zi-Jin Wei,Zichao Yan,Kai Long,Yuan Tian,Yifei Wang,Wei Wang,Zhi Yuan
Photodynamic therapy (PDT) has emerged as a powerful candidate for cancer intervention as for the merits of least-invasiveness, multidrug resistance-free and spatiotemporal selectivity. Whereas, clinical photosensitizers (PSs) suffer from microsecond-level reactive oxygen species (ROS) lifetime requiring 20–30 min continuous exterior light stimulation, deficient photostable nature and off-target phototoxicity in nonmalignant tissues. Persistent luminescence nanoparticles (PLNPs), are proven to exert long-lasting ROS production after the excitation cessation (hours to days), and serve as photostable imaging agent for diagnose. Herein, a traceable theranostic agent, ZP@PCM PLNPs is prepared by modifying polyaniline (PANI) onto Zn 1.2 Ga 1.6 Ge 0.2 O 4 : Cr 3+ (ZGGC) to obtain ZP PLNPs and wrapping phase-change material (PCM) as outer protective shell. Solid-phase PCM isolates inner ZP PLNPs from surrounding oxygen during circulation to circumvent off-target photosensitization. Once ZP@PCM PLNPs accumulated within tumors, external laser triggered PANI assisted photothermal therapy (PTT) initiates, and thermal melting of PCM shell occurs leading to the exposure of ZP PLNPs to switch on PDT. PANI also facilitates PDT efficacy optimization, enabling ZP PLNPs of 2-fold ROS yield compared to ZGGC PLNPs, sustained up to 48 h upon 10 min of illumination. ZP@PCM PLNPs with long-term, moderate therapy modality presents ameliorated anti-tumor effect, achieving tumor inhibition rate of 92.2 % over that of ∼ 46 % with individual ZGGC PLNPs, and shows satisfactory biosafety without tissues damage or inflammatory response. Meanwhile, the autofluorescence-free visualization potency helps to self-report therapeutic outcomes and determine treatment duration. Overall, ZP@PCM PLNPs provide a promising PSs-free alternative candidate for finely controlled PDT/PTT and visualization tumor therapy.
研究领域:
纳米技术
·
生物医学工程
·
癌症治疗
·
材料科学
·
诊疗学
✓ 已验证
产品关联
DOI
高影响因子
NANOTECHNOLOGY
·
2021
·Vol. 32
·期 45
·455101
·
IF 3.874
Xiaojing Yang,Di-Feng Chen,Lin-Song Li,Xue-Jie Zhao,Mei-Xia Zhao
In this study, a nanodrug carrier (mesoporous silica nanoparticle (MSN)-SS-cysteamine hydrochloride (CS)-hyaluronic acid (HA)) for targeted drug delivery was prepared using MSNs, in which HA was used as a targeting ligand and blocking agent to control drug release. Coumarin is a fluorescent molecule that targets mitochondria. Two conjugates (XDS-DJ and 5-FUA-4C-XDS) were synthesized by chemically coupling nitrogen mustard and 5-fluorouracil with coumarin, which was further loaded into MSN-SS-CS-HA nanocarriers. MTT analysis demonstrated that the nanocomposite MSN-SS-CS@5-FUA-4C-XDS/HA displayed stronger cytotoxicity toward HCT-116 cells than HeLa or QSG-7701 cells. Furthermore, MSN-SS-CS@5-FUA-4C-XDS/HA was able to target the mitochondria of HCT-116 cells, causing decreased mitochondrial membrane potential and excessive production of reactive oxygen species. These results indicate that MSN-SS-CS@5-FUA-4C-XDS/HA has the potential to be a nanodrug delivery system for the treatment of colon cancer.
研究领域:
纳米技术
·
药学
·
癌症研究
·
生物医学工程
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）